by Asmaa Javed | Dec 30, 2019 | Press Releases
The US Food and Drug Administration has granted a Breakthrough Therapy Designation to cobimetinib in the treatment of patients with histiocytic neoplasms (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not bear the BRAF V600 mutation. This...
by Asmaa Javed | Dec 30, 2019 | Press Releases
MD Anderson Cancer Center in Houston, Texas takes lead on Dabrafenib and Trametinib drug trial.
by Asmaa Javed | Dec 31, 2018 | Press Releases
The ECD Global Alliance awards an Erdheim-Chester disease research grant to MSKCC to define the disease-initiating cell population in ECD and compare genetic alterations.
by Asmaa Javed | Dec 31, 2018 | Press Releases
The ECD Global Alliance welcomes Duke Cancer Institute in Durham, NC into the referral care center network that serves ECD patients worldwide. Richard F. Riedel, MD will be leading the institute’s team at the Emerging Referral Care Center.
by Asmaa Javed | Dec 31, 2018 | Press Releases
The ECD Global Alliance announces the launch of the Registry for Patients with Erdheim-Chester Disease led by Memorial Sloan Kettering Cancer Center (MSK), in New York, NY. The next step in building the registry database includes recruiting patients with ECD to...
by Asmaa Javed | Dec 31, 2018 | Press Releases
Medical residents and physicians at Houston Methodist Hospital in Houston, TX learned about Erdheim-Chester disease from ECD Care Center lead, Mark Heaney, MD, PhD from Columbia University Medical Center. Also in attendance was ECDGA President, Kathy Brewer.
